MF001 relieved alcohol-induced inflammation and fatty liver symptoms in mice. by Eun-Ho Lee (2696890)

Subjects:

MF001 attenuates alcohol-induced fatty liver phenotypes in mice. by Eun-Ho Lee (2696890)

Subjects:

MF001 reduces the expression of lipogenic genes and proteins. by Eun-Ho Lee (2696890)

Subjects:

MF001 reduces lipid accumulation and peroxidation in liver tissues. by Eun-Ho Lee (2696890)

Subjects:

S1 File - A novel yeast-derived aldehyde-reducing compound MF001 protects against alcohol-induced liver damage by Eun-Ho Lee (2696890)

Subjects:

MF001 protects against alcohol-induced liver inflammation. by Eun-Ho Lee (2696890)

Subjects:

MF001 ameliorated alcohol-induced fatty liver phenotypes in mice. by Eun-Ho Lee (2696890)

Subjects:

MF001 alleviates lipid accumulation in primary hepatocytes. by Eun-Ho Lee (2696890)

Subjects:

MF001 liberates alcohol-induced lipogenesis in mice. by Eun-Ho Lee (2696890)

Subjects:

Clinical diagnosis and abnormal signals of AEFIs(/10,000). by Chao Zhang (51048)

Subjects:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Changes in reported rate of AEFIs in the pre-LAW and post-LAW period(/10000). by Chao Zhang (51048)

Subjects:

Data. by Chao Zhang (51048)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Characteristics of AEFIs with JEV-L vaccine in the pre-LAW and post-LAW period. by Chao Zhang (51048)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects: